title: Concentrations of altrenogest in plasma of mares and foals and in allantoic and amniotic fluid at parturition.
abstract: Treatment with the progestin altrenogest is widely used in pregnant mares. The fact that foals born from healthy mares treated with altrenogest until term suffered from neonatal problems raises the question of direct effects of altrenogest on vital functions in the neonate. We have therefore investigated altrenogest concentrations in maternal and neonatal blood plasma and in fetal fluids. Pregnant mares were treated with altrenogest orally once daily (0,088 mg/kg bodyweight, n = 7) or left untreated (n = 8) from 280 d of gestation until foaling. Altrenogest concentration was determined in plasma of the mares, their foals and in amniotic and allantoic fluid. The concentration of altrenogest in plasma from treated mares (2.6 +/- 1.0 ng/mL) was significantly lower than in plasma from their foals immediately after birth (5.6 +/- 1.9 ng/mL; p < 0.05), but was significantly higher than in their fetal fluids (amniotic fluid: 0.4 +/- 0.1 ng/mL; p < 0.05; allantoic fluid: 3.0 +/- 1.5 ng/mL). Altrenogest was undetectable in maternal and fetal plasma and fetal fluids of control pregnancies at all times. Altrenogest concentration in plasma of foals from treated mares was strongly correlated to the altrenogest concentration in plasma of their dams (r = 0.938, p < 0.001) and in amniotic (r = 0.886, p < 0.001) and allantoic fluid (r = 0.562, p < 0.05). A significant decrease in altrenogest concentration between the time periods 0-15 min, 30-120 min, and 180-360 min after parturition was seen in the plasma from foals born to altrenogest-treated mares. In conclusion, our data demonstrate that altrenogest reaches the equine fetus at high concentrations.
authors.affiliation: Clinic for Obstetrics, Gynecology and Andrology, University for Veterinary Sciences, Vienna, Austria.
authors.forename: Franziska M
authors.initials: FM
authors.lastname: Palm
authors.forename: Ina
authors.initials: I
authors.lastname: Schenk
authors.forename: Stefanie
authors.initials: S
authors.lastname: Neuhauser
authors.forename: Daniel
authors.initials: D
authors.lastname: Schubert
authors.forename: Marc
authors.initials: M
authors.lastname: Machnik
authors.forename: Wilhelm
authors.initials: W
authors.lastname: Schänzer
authors.forename: Christine
authors.initials: C
authors.lastname: Aurich
mesh_terms: D000482:Allantois / Q000378:metabolism; D000653:Amniotic Fluid / Q000378:metabolism; D000818:Animals; D000831:Animals, Newborn / Q000097:blood*; D005260:Female; D006736:Horses / Q000097:blood / Q000378:metabolism*; D008431:Maternal-Fetal Exchange; D036801:Parturition / Q000378:metabolism; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D045167:Progesterone Congeners / Q000009:adverse effects / Q000097:blood* / Q000378:metabolism / Q000627:therapeutic use; D014204:Trenbolone Acetate / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use
chemical_list: D045167:Progesterone Congeners; C023445:altrenogest; D014204:Trenbolone Acetate